Blockade of VEGF-induced GSK/β-catenin signaling, uPAR expression and increased permeability by dominant negative p38α
- 1 July 2012
- journal article
- research article
- Published by Elsevier in Experimental Eye Research
- Vol. 100, 101-108
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (EY004618, EY011766)
- American Historical Association
This publication has 41 references indexed in Scilit:
- The Pathogenic Role of the Canonical Wnt Pathway in Age-Related Macular DegenerationInvestigative Ophthalmology & Visual Science, 2010
- Antipermeability Function of PEDF Involves Blockade of the MAP Kinase/GSK/β-Catenin Signaling Pathway and uPAR ExpressionInvestigative Ophthalmology & Visual Science, 2010
- Activation of the Wnt Pathway Plays a Pathogenic Role in Diabetic Retinopathy in Humans and Animal ModelsThe American Journal of Pathology, 2009
- Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusionBritish Journal of Ophthalmology, 2008
- A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular EdemaOphthalmology, 2007
- Proteolytic Degradation of VE-Cadherin Alters the Blood-Retinal Barrier in DiabetesDiabetes, 2007
- Activation and signaling of the p38 MAP kinase pathwayCell Research, 2005
- Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4Experimental & Molecular Medicine, 2004
- In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathyGene Therapy, 2003
- Urokinase Plasminogen Activator/Urokinase-specific Surface Receptor Expression and Matrix Invasion by Breast Cancer Cells Requires Constitutive p38α Mitogen-activated Protein Kinase ActivityJournal of Biological Chemistry, 2000